Literature DB >> 17192304

Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Andrea Hesse1, Daniela Kosmides, Roland E Kontermann, Dirk M Nettelbeck.   

Abstract

Recombinant adenoviruses have emerged as promising agents in therapeutic gene transfer, genetic vaccination, and viral oncolysis. Therapeutic applications of adenoviruses, however, would benefit substantially from targeted virus cell entry, for example, into cancer or immune cells, as opposed to the broad tropism that adenoviruses naturally possess. Such tropism modification of adenoviruses requires the deletion of their natural cell binding properties and the incorporation of cell binding ligands. The short fibers of subgroup F adenoviruses have recently been suggested as a tool for genetic adenovirus detargeting based on the reduced infectivity of corresponding adenovectors with chimeric fibers in vitro and in vivo. The goal of our study was to determine functional insertion sites for peptide ligands in the adenovirus serotype 41 (Ad41) short fiber knob. With a model peptide, CDCRGDCFC, we could demonstrate that ligand incorporation into three of five analyzed loops of the knob, namely, EG, HI, and IJ, is feasible without a loss of fiber trimerization. The resulting adenovectors showed enhanced infectivity for various cell types, which was superior to that of viruses with the same peptide fused to the fiber C terminus. Strategies to further augment gene transfer efficacy by extension of the fiber shaft, insertion of tandem copies of the ligand peptide, or extension of the ligand-flanking linkers failed, indicating that precise ligand positioning is pivotal. Our study establishes that internal ligand incorporation into a short-shafted adenovirus fiber is feasible and suggests the Ad41 short fiber with ligand insertion into the top (IJ loop) or side (EG and HI loops) of the knob domain as a novel platform for genetic targeting of therapeutic adenoviruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192304      PMCID: PMC1865974          DOI: 10.1128/JVI.02722-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

2.  Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob.

Authors:  Taco G Uil; Toshiro Seki; Igor Dmitriev; Elena Kashentseva; Joanne T Douglas; Marianne G Rots; Jaap M Middeldorp; David T Curiel
Journal:  Cancer Gene Ther       Date:  2003-02       Impact factor: 5.987

3.  Flexibility of the adenovirus fiber is required for efficient receptor interaction.

Authors:  Eugene Wu; Lars Pache; Dan J Von Seggern; Tina-Marie Mullen; Yeshi Mikyas; Phoebe L Stewart; Glen R Nemerow
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber.

Authors:  Takafumi Nakamura; Kenzo Sato; Hirofumi Hamada
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism.

Authors:  Karine Martin; Anne Brie; Patrick Saulnier; Michel Perricaudet; Patrice Yeh; Emmanuelle Vigne
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

6.  Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates.

Authors:  Theodore A G Smith; Neeraja Idamakanti; Jennifer Marshall-Neff; Michele L Rollence; Patrick Wright; Michele Kaloss; Laura King; Christine Mech; Lisa Dinges; William O Iverson; Alfred D Sherer; Judit E Markovits; Russette M Lyons; Michael Kaleko; Susan C Stevenson
Journal:  Hum Gene Ther       Date:  2003-11-20       Impact factor: 5.695

7.  Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.

Authors:  Dirk M Nettelbeck; Angel A Rivera; Cristina Balagué; Ramon Alemany; David T Curiel
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

8.  Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA.

Authors:  Dirk M Nettelbeck; Angel A Rivera; Jörg Kupsch; Detlef Dieckmann; Joanne T Douglas; Roland E Kontermann; Ramon Alemany; David T Curiel
Journal:  Int J Cancer       Date:  2004-01-01       Impact factor: 7.396

9.  Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism.

Authors:  Andrea L Volk; Angel A Rivera; Anna Kanerva; Gerd Bauerschmitz; Igor Dmitriev; Dirk M Nettelbeck; David T Curiel
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

10.  Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice.

Authors:  Theodore A G Smith; Neeraja Idamakanti; Michele L Rollence; Jennifer Marshall-Neff; Jin Kim; Kathy Mulgrew; Glen R Nemerow; Michael Kaleko; Susan C Stevenson
Journal:  Hum Gene Ther       Date:  2003-05-20       Impact factor: 5.695

View more
  16 in total

1.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

2.  Amino acid exchanges in the putative nuclear export signal of adenovirus type 5 L4-100K severely reduce viral progeny due to effects on hexon biogenesis.

Authors:  Orkide O Koyuncu; Thomas Speiseder; Thomas Dobner; Melanie Schmid
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

3.  Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

Authors:  Xavier Allaume; Nazim El-Andaloussi; Barbara Leuchs; Serena Bonifati; Amit Kulkarni; Tiina Marttila; Johanna K Kaufmann; Dirk M Nettelbeck; Jürgen Kleinschmidt; Jean Rommelaere; Antonio Marchini
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

4.  Serotype 5 Adenovirus fiber (F7F41S) chimeric vectors incur packaging deficiencies when targeting peptides are inserted into Ad41 short fiber.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  Virology       Date:  2009-09-25       Impact factor: 3.616

5.  A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Authors:  Q Shi; A T Nguyen; Y Angell; D Deng; C-R Na; K Burgess; D D Roberts; F C Brunicardi; N S Templeton
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

6.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

7.  Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006.

Authors:  Gregory C Gray; Troy McCarthy; Mark G Lebeck; David P Schnurr; Kevin L Russell; Adriana E Kajon; Marie L Landry; Diane S Leland; Gregory A Storch; Christine C Ginocchio; Christine C Robinson; Gail J Demmler; Michael A Saubolle; Sue C Kehl; Rangaraj Selvarangan; Melissa B Miller; James D Chappell; Danielle M Zerr; Deanna L Kiska; Diane C Halstead; Ana W Capuano; Sharon F Setterquist; Margaret L Chorazy; Jeffrey D Dawson; Dean D Erdman
Journal:  Clin Infect Dis       Date:  2007-09-27       Impact factor: 9.079

8.  Effective modifications for improved homologous recombination and high-efficiency generation of recombinant adenovirus-based vectors.

Authors:  Chengxiang Wu; Vivek R Nerurkar; Richard Yanagihara; Yuanan Lu
Journal:  J Virol Methods       Date:  2008-09-11       Impact factor: 2.014

9.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 10.  Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.